Drug Profile

JS 212

Alternative Names: JS-212

Latest Information Update: 05 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Junshi Biosciences
Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Dec 2025 Shanghai Junshi Bioscience plans a phase II trial for Lung cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in China (IV, Infusion) (NCT07309276)
11 Apr 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT06888830)
25 Mar 2025 Shanghai Junshi Bioscience plans a phase I/II trial for Solid tumours (Late-stage disease) in China (Parenteral, Injection) in April 2025 (NCT06888830)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com